GO
Loading...

Medicine

More

  • In the wake of my semantic disagreement with Amgen over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number.

  • AMGEN

    I just got back to my desk after doing a breaking news alert on Amgen's earnings. To sum up, I characterized the report as a mixed bag. The anemia drug sales weren't as bad as expected. Overall revenue was higher than consensus. And fourth quarter earnings per share was three cents higher than the Street.

  • Merck And Schering Reeling From Vytorin Study Thursday, 24 Jan 2008 | 1:56 PM ET

    ImpactRx--which follows prescription writing for the industry, investors and analysts--is out with a press release this afternoon assessing the damage to Merck and Schering-Plough's cholesterol franchise of Vytorin and Zetia.

  • Pfizer's Earnings: Reviews Are In, But Thumbs Up Or Down? Thursday, 24 Jan 2008 | 12:22 PM ET

    After yesterday's beat and boost by drug giant Pfizer and a late-day rally in the stock, analysts are providing clients their take on the numbers as the shares traded lower in the early going. Deutsche Bank's Barbara Ryan is keeping her long-standing "Buy" rating on PFE, even though she told me recently she's been "long and wrong" on the stock.

  • Pfizer Doing Its "Best" To Help Dow And Pharma Sector Wednesday, 23 Jan 2008 | 11:27 AM ET

    As I write this at the start of the second hour of regular trading, Pfizer is hangin' on to a small gain. It's the only big pharma stock trading higher this morning and for a moment after the opening bell it was the only Dow component in the green. (Merck and Schering-Plough, still reeling from the Vytorin/Zetia study, are getting pummeled again in the early going--each down more than a buck.)

  • This press release and letters to the CEOs of MRK and SGP from the House Energy and Commerce Committee just arrived in my inbox:

  • Merck, SGP Go On A Vytorin "Offensive" Tuesday, 22 Jan 2008 | 11:22 AM ET

    I'm blogging today from outside the New York Stock Exchange where I'm trying to round up "man-on-the-(Wall) street" reaction to the markets. In the meantime, back on the beat, for the second day Merck and Schering-Plough have taken out two-page ads in major newspapers defending their cholesterol drugs Zetia and Vytorin whose efficacy is under attack.

  • Dendreon's Provenge: No Congressional Decision-YET Friday, 18 Jan 2008 | 4:04 PM ET

    I blogged recently that a spokesperson for the House Energy and Commerce Committee had told me a decision could be made by the end of this week regarding the Dendreon saga.

  • SGP's CEO Hassan: Putting Money Where His Mouth Is Friday, 18 Jan 2008 | 12:58 PM ET

    After watching his stock lose more than one-fifth of its value this week, Schering-Plough CEO Fred Hassan apparently decided the shares are on sale. This morning the company issued a press release announcing Hassan (pronounced Haa-sun, not the commonly mispronounced Huh-sahn) will shell out $2 million of his own money to buy SGP shares on the open market.

  • Pfizer's Chantix Warning: Hazardous To Mental Health? Friday, 18 Jan 2008 | 10:35 AM ET

    This doesn't come as any big surprise, but Pfizer announced this morning that it is putting a warning--and that's the company's word--on the label of its stop-smoking pill Chantix. It says people taking the drug should be watched for "serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior."

  • Pharma Investors: Will Political Talk Scare Them Off? Thursday, 17 Jan 2008 | 10:32 AM ET

    If or when you watch one of the presidential  debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...

  • Merck, Schering in Vytorin Victory Wednesday, 16 Jan 2008 | 12:40 PM ET

    The American College of Cardiology is weighing in on the controversial ENHANCE study that has battered shares of Merck and Schering-Plough over the past couple of days. Most notably I think is that the ACC says, "There should be no reason for patients to panic."

  • Pfizer's Chantix Is "Smokin'" Again Tuesday, 15 Jan 2008 | 10:52 AM ET

    I had planned to blog about the nearly unanimous bearish analyst commentary this morning after Genentech's earnings report yesterday. The biotech giant beat on earnings per share, but came up short on Street expectations for sales of its top four drugs. DNA shares are under pressure again today.

  • Novo Nordisk: A Big "No" To Inhaled Insulin--For Now Tuesday, 15 Jan 2008 | 8:11 AM ET

    In the wake of Pfizer pulling the plug on its poor-selling inhaled insulin Exubera, the world's biggest diabetes drug company, Novo Nordisk is throwing in the towel on development of its version of inhaled insulin.

  • Merck And Schering Plough: "Enhancing" A Franchise? Monday, 14 Jan 2008 | 2:13 PM ET

    The highly anticipated results of the study that goes by the acronym "ENHANCE" are out this morning. You can see what it stands for in the companies' press release. (I wonder how many meetings and brainstorming sessions go into coming up with some of the industry's clinical trial acronyms and abbreviations.)

  • Dendreon's Saga Over Provenge "Edited Up" A Notch Friday, 11 Jan 2008 | 1:09 PM ET

    The brouhaha over the Food and Drug Administration's delay of the potential approval of the prostate cancer drug Provenge from the small biotechnology company Dendreon is now entering the prestigious and credible sphere of peer-reviewed scientific journals.

  • Eli Lilly

    Even though I'm back on the East Coast today I wanted to share what I think is an interesting anecdote from my time Monday at the JPMorgan Healthcare Conference which is wrapping up in San Francisco.

  • FDA In 2007: Not Much Love For New Drugs Wednesday, 9 Jan 2008 | 1:52 PM ET

    BioMed Tracker, which closely monitors the clinical trial and drug approval process for investors, is out with a new report today on the Food and Drug Administration's record last year. The drug approval rate went down 13 percent and the number of "approvable letters" went up a whopping 40 percent. An approvable letter has become a euphemism for "delay."

  • Amgen And Me: We're Still On The "Wrong" Foot Tuesday, 8 Jan 2008 | 3:56 PM ET
    AMGEN

    So, imagine my surprise when Amgen put out a press release this morning with new financial guidance. You can read it for yourself here. The release was issued in conjunction with the company's presentation at the JPMorgan Healthcare Conference.

  • Genzyme And Isis Steal Show With Cholesterol Drug Tuesday, 8 Jan 2008 | 10:28 AM ET

    After the closing bell Monday, Genzyme and Isis Pharmaceuticals announced a blockbuster deal that set the overcrowded halls abuzz here at the JPMorgan Healthcare Conference. They're partnering on an Isis drug in late-stage development for cholesterol. It's a once-a-week injectable for people who don't get their cholesterol low enough taking a statin like Lipitor, Crestor or Zocor.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.